After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to unlock its next chapter of mental health treatment. TEV’749 is a long-acting ...
Hosted on MSN
Luye Pharma grants NHWA exclusive China rights for three long-acting schizophrenia drugs
Luye Pharma Group ( (HK:2186)) has provided an announcement. Luye Pharma Group has granted Jiangsu Nhwa Hexin Pharmaceutical Marketing, a subsidiary of CNS-focused specialist Jiangsu Nhwa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results